These trials consistently demonstrated higher response rates and longer progression-free survival (PFS) with EGFR TKI treatment in patients with EGFR mutant NSCLC, which resulted in EGFR TKIs being used as the standard first-line therapy [11–13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.